Trial Outcomes & Findings for Study of Nasonex® in Improving Sleep Disturbances Related to Perennial Allergic Rhinitis (Study P04909)(TERMINATED) (NCT NCT00491374)

NCT ID: NCT00491374

Last Updated: 2009-01-06

Results Overview

Recruitment status

TERMINATED

Study phase

PHASE4

Results posted on

2009-01-06

Participant Flow

No subject fulfilled the requirements for randomized assignment of treatment; thus, no subject was assigned an intervention, and no subject was treated. The trial was terminated.

Participant milestones

Participant milestones
Measure
Placebo
Mometasone Furoate Nasal Spray
Overall Study
STARTED
0
0
Overall Study
COMPLETED
0
0
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Study of Nasonex® in Improving Sleep Disturbances Related to Perennial Allergic Rhinitis (Study P04909)(TERMINATED)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Placebo
Mometasone Furoate Nasal Spray
Total
Total of all reporting groups
Age, Customized
Any Age
0 participants
n=5 Participants
0 participants
n=7 Participants
0 participants
n=5 Participants
Sex/Gender, Customized
Either Sex
0 participants
n=5 Participants
0 participants
n=7 Participants
0 participants
n=5 Participants

PRIMARY outcome

Population: The primary outcome measure could not be assessed because no subject received randomized treatment assignment, or any treatment. The study was terminated.

Outcome measures

Outcome measures
Measure
Placebo
Mometasone Furoate Nasal Spray
The Change From Baseline in the Number of Apnea-hypopnea Episodes Per Hour (Apnea-hypopnea Index (AHI)
0 (NUMBER)
0 (NUMBER)

Adverse Events

Placebo

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Mometasone Furoate Nasal Spray

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Head, Clinical Trials Registry & Results Disclosure Group

Schering-Plough

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: OTHER